THE MEDICAL NEWS: As hundreds of prostate cancer researchers, advocates and supporters Advance on Washington this week and push for more progress in fighting the disease, the Prostate Cancer Foundation applauds the prostate cancer legislation introduced on Tuesday by Senator Jon Tester of Montana. READ MORE> and HERE>
Archive for the ‘OFFICIAL BODIES’ Category
Posted in OFFICIAL BODIES, tagged Advance on Washington, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer legislation, prostate cancer researchers, prostate treatment debate, Screening debate, Senator Jon Tester, THE MEDICAL NEWS, US Prostate Cancer Foundation on September 19, 2010| 1 Comment »
Posted in Govt prostate policy, PROSTATE RESEARCH, Public health system, tagged breast cancer, cancer death rates, cancer diagnosis, cancer research, catheter, colorectal cancer, deprivation and cancer, lung cancer, Maori, Maori and prostate cancer, Maori health, non-Maori health, NZ cancer statistics, NZ Ministry of Health, prostablog, prostate, prostate blog, PROSTATE CANCER, racialised society, socioeconomic status and cancer on August 25, 2010| Leave a Comment »
PROSTABLOG NZ: If you’re Maori and poor in New Zealand, you have less chance of being diagnosed early with prostate cancer – and you’re got a 60% greater chance than non-Maori of dying .
These and other findings are in a major new report just released by the NZ Ministry of Health, whose researchers looked at cancer trends in the five years 2002 to 2006 and compared rates with ethnicity (Maori and non-Maori) and socio-economic status (deprivation) and where people live.
Some quotes from the report:
Prostate cancer was…more common among non-Māori men, but Māori death rates were higher than those of non-Māori men.
On average, just over 130 Māori men were diagnosed with prostate cancer each year, and around 33 died from the disease during 2002–2006.
Among non-Māori men, on average 2,495 per year were diagnosed with prostate cancer and nearly 540 per year died from the cancer. The Māori age-standardised registration rate was about 10% lower than the non-Māori rate while the death rate was 60% higher.
Over the period 1996–2006, there were no significant changes in incidence or mortality for Māori men. Among non-Māori men there was no change in incidence but there was a significant decrease in mortality of 2% per year.
Prostate cancer incidence was associated with increasing deprivation for Māori men but not for non-Māori.
Prostate cancer incidence was significantly lower among Māori and non-Māori rural residents compared to main urban residents.
Only a small proportion of lung, prostate cancers and around a third of stomach cancers were diagnosed at the earlier stages of disease spread.
…Māori had significantly lower odds than non-Māori of being diagnosed at a localised stage, and higher odds of being diagnosed at a distant stage for most of the key cancers (breast, cervical, colorectal, lung, and prostate cancers).
During the period 1996–2006, Māori had a significantly higher age-adjusted risk of dying from their cancer after diagnosis compared to non-Māori…The relative risks ranged from 24% higher for lung and stomach cancers to 103% higher for prostate cancer.
For prostate cancer, gaps between Māori and non-Māori are wider outside main urban centres. Both Māori and non-Māori with prostate cancer have worse survival outcomes outside main urban centres, but the difference is greater for Māori patients.
Among non-Māori, increasing deprivation was significantly associated with poorer survival chances for breast, colorectal, lung, prostate, and uterine cancers.
Among Māori, rural residents had significantly lower survival (or higher death rates) than their main urban counterparts for prostate and uterine cancers. Among non-Māori, rural residents had significantly lower survival from colorectal, lung, and prostate cancers.
Within each rural–urban area, Māori had higher risk than non-Māori of dying from their cancer after diagnosis.
Disparities in cancer incidence and outcomes persist in Aotearoa/New Zealand, although there is promising movement towards equity for specific cancers, such as cervical cancer.
…ethnic disparities in socioeconomic status and in other social and environmental determinants of health result from the entrenched unequal power relations that underpin and sustain a racialised society.
…there is some evidence to suggest that socio-economic inequalities in cancer mortality are growing over time.
Similarly to mortality trends, there is some suggestion of increasing socio-economic disparities in survival in recent decades. Improvements in survival are generally larger for those people residing in affluent areas compared to those living in deprived areas for many cancers.
…participants in studies of Māori health care experiences report significant hardships resulting from the hidden costs of ‘distance deprivation’ among rural residents, particularly for those with low incomes.
For Māori, the age-sex-standardised incidence rate for all cancers combined was 220.4 per 100,000, 19% higher than the non-Māori rate of 185.2 per 100,000. The cancer death rate for this period was 112.0 per 100,000 for Māori, 78% higher than the rate for non-Māori of 63.3 per 100,000 (Figure 2.1).
Lung cancer was the most commonly occurring cancer for Māori overall, accounting for 20% of all cancers (compared to 9% for non-Māori). Breast, prostate, colorectal, and stomach cancers were the next most frequent.
Among non-Māori, the most common types were colorectal, prostate, breast, melanoma of the skin, and lung cancer. These patterns were also consistent across each rural–urban area, except for non-Māori in rural areas where prostate ranked highest and melanoma third.
Among Māori males, lung cancer (20%) and prostate cancer (20%) were the most common (registrations), followed by colorectal (9%), stomach (5%) and liver cancer (5%). For non-Māori males, prostate cancer was the most common (28%)…
Lung cancer was the leading cause of cancer death, accounting for 31% of Māori and 17% of non-Māori cancer deaths.
Female breast, colorectal, stomach and prostate cancers were the next most common for Māori. Among non-Māori males, lung, colorectal, prostate, cancers of unknown primary site, and melanoma were the leading causes of cancer death.
Among Māori, lung, breast, prostate and colorectal were the four leading cancer sites across all deprivation quintiles, with some variation across quintiles. Prostate, colorectal, breast, melanoma and lung were the five leading sites for non-Māori in all quintiles, with colorectal leading in the three most deprived quintiles.
Among non-Māori, the deprivation gradients were steepest for deaths from cervical, oral, and lung cancers. Other cancers with a significant deprivation gradient for non-Māori included cancers of the thyroid, liver, stomach, uterus, pancreas, bladder, oesophagus and prostate.
Our results suggest that substantial undercount of Māori cancer registrations still exist, despite the improvement in the count of Māori registrations from the new ethnicity algorithm. The undercount ranges from approximately 2% to 22% depending on age.
PROSTABLOG NZ: If only 3% of US men diagnosed with prostate cancer die, what’s happening in NZ, where the proportion is 20%?
The 3% figure pops up in Mike Scott‘s latest discussion on PSA testing for prostate cancer, when he says:
…the number of men in America who die of prostate cancer today is believed to be significantly less than three for every 100 men diagnosed. (New Prostate Cancer Infolink)
Compare that with NZ, where about 3000 prostate cancer diagnoses are registered each year – and 600 men die each year. That’s 20%.
Does the NZ Ministry of Health have some explaining to do?
Read Mike’s discussion HERE>
Posted in PROSTATE CANCER, PROSTATE RESEARCH, Public health system, tagged biggest cancer killer, cancer research, catheter, Minister of Health, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate diagnosis, Tony Ryall on July 4, 2010| 1 Comment »
Posted in PROSTATE CANCER, Public health system, tagged cancer research, catheter, colorectal cancer, melanoma, NZ cancer deaths, NZ cancer statitics, NZ Ministry of Health, prostablog, prostate, prostate blog, PROSTATE CANCER on June 30, 2010| Leave a Comment »
Posted in Govt prostate policy, SELECT COMMITTEE INQUIRY, tagged catheter, Health Select Committee inquiry, Listener, NZ Ministry of Health, NZ Parliament; Health select committee, Paul Hutchison, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, PSA, PSA test, Screening debate on February 26, 2010| 3 Comments »
PROSTABLOG NZ: The ideological debate about prostate cancer screening hasn’t moved along much in New Zealand over the past few years.
I’m judging this from an anecdote a guest speaker at my journalism course told students this week.
An experienced journalist, she said a few years ago she was writing a piece for NZ Listener magazine about PSA screening, and the Ministry of Health would speak to her only on the condition they got to see the resulting article prior to publication.
That usually causes journalists to feel apprehensive, and in this case her fears were realised.
The Ministry people hit the roof over what she wrote (basically, that all men over 50 should be urged to get PSA tests), and made this plain to her editor.
Judging by what I heard from the Ministry team at the Health Select Committee hearing into prostate cancer screening late last year, the official view is still the same: PSA bad.
Speaking of which – I wonder when we’re going to hear anything further from the committee?
Chairman Paul Hutchison made the MOH people promise to deliver their final views last November.
Are there more hearings?
When will we see the results?
Posted in Govt prostate policy, PROSTATE RISKS, PSA tests, Public health system, SCREENING and DIAGNOSIS, tagged cancer research, catheter, medical checkups, Ministry of Health, NZ, NZ Ministry of Health cancer report, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer projections, prostate cancer screening, prostate treatment debate, prostate-specific antigen, PSA, PSA effect, PSA test, Screening debate on February 10, 2010| 3 Comments »
PROSTABLOG NZ: Rates of prostate cancer detected in NZ are expected to rise about 23% in the decade leading up to 2016, moving from 91 cases per 100,000 to 112.
That’s the finding of a Ministry of Health cancer projection report released late last month, but only just picked up by news media (none of whom looked in detail at prostate cancer).
Something the report calls the “burden of new cases” is expected to increase by 71% over the 2006-2016 period. This term is not explained (for the uninitiated).
Interpreting the report is something of a challenge.
The Ministry’s researchers have chosen to single out prostate cancer projections as the only ones that “could not be updated (although they have been extended), as these are based only on data up to 1984-88”.
The reason given is something they dub the “PSA effect”.
It’s hard to be sure, but this apparently means that because of a sudden upsurge of PSA testing in the late 1980s and early 1990s – leading to perhaps half of the Kiwi aged male population getting tested – there has been a massive blip in the detection statistics.
A half generation of men who would otherwise have not been detected until symptoms showed at an older age have been diagnosed “early”.
This has distorted trends to such an extent, it seems, the projection models can’t cope.
Graphs from the report, reproduced here, show the “bulge” effect. In the bottom one, the solid lines showing rates up to 2006 are extrapolated out (dotted lines) from 1986, ignoring what really happened because of PSA testing:
The Ministry says until rates return to what would have been expected “pre-PSA”, it cannot provide reliable predictions.
Despite that constraint, it has a go anyway: it concludes the rate of prostate cancer will continue to rise (presumably because of the baby boomer bulge moving through).
Confused? Join the club.
Why is prostate cancer being dealt with differently from other cancers that have been the subject of widespread screening and marketing campaigns, such as breast and cervical?
Is it because those screening campaigns were Ministry-approved, while PSA is frowned on by the Ministry because it leads to a problem – once prostate cancer is found there is no reliable way to know if it needs treatment, leading to possible over-treatment, and with it, unnecessary cost on the health system.
It would be useful to hear from epidemiologists on this, despite their inherent bias against PSA testing casting doubt on their views.
Still, they might help unravel the technicalities of the Ministry’s convoluted explanation.